- Trials with a EudraCT protocol (4,086)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (98)
4,086 result(s) found for: Lesion.
Displaying page 1 of 205.
EudraCT Number: 2010-019422-13 | Sponsor Protocol Number: 2010-1 | Start Date*: 2010-08-03 |
Sponsor Name:Medical University of Graz | ||
Full Title: An open monocentric pilot study to investigate the potential of imiquimod 5% cream to detect residual and to prevent recurrence of lentigo maligna after surgical excision | ||
Medical condition: An open monocentric pilot study to investigate the potential of imiquimod 5% cream to detect residual and to prevent recurrence of lentigo maligna after surgical excision | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003946-18 | Sponsor Protocol Number: GDX-44-011 | Start Date*: 2019-05-03 | |||||||||||
Sponsor Name:GUERBET | |||||||||||||
Full Title: Efficacy and safety of gadopiclenol for body magnetic resonance imaging (MRI) | |||||||||||||
Medical condition: Patients presenting with know or suspected enhancing abnormality(ies) and/or lesion(s) in at least one body region among head & neck, thorax (including breast), abdomen (including liver, pancreas a... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Completed) BG (Completed) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000880-26 | Sponsor Protocol Number: HTX101-02G | Start Date*: 2019-09-03 | |||||||||||
Sponsor Name:Heidelberg ImmunoTherapeutics GmbH | |||||||||||||
Full Title: A Randomized, Double-Blind, Double-Dummy Phase II Study of Single Dose HDIT101 versus Standard of Care Valaciclovir in Patients with Chronic Recurrent Anogenital HSV-2 Infection | |||||||||||||
Medical condition: Chronic recurrent anogenital HSV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006135-29 | Sponsor Protocol Number: PH-107 | Start Date*: 2012-09-03 | |||||||||||
Sponsor Name:Bracco Imaging S.p.A. | |||||||||||||
Full Title: PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF PROHANCE® WITH 0.1 mmol/kg OF GADOVIST®/GADAVIST™ IN MAGNETIC RESONANCE IMAGING (MRI) OF THE BRAIN (TRUTH) | |||||||||||||
Medical condition: Have confirmed or are highly suspected of brain disease likely to enhance as determined by the following: clinical/neurological symptomatology; diagnostic testing, such as CT or previous MRI exam... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003576-23 | Sponsor Protocol Number: GDX-44-004 | Start Date*: 2016-01-28 | ||||||||||||||||
Sponsor Name:GUERBET | ||||||||||||||||||
Full Title: P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) | ||||||||||||||||||
Medical condition: Subject presenting, at the time of inclusion, with known or highly suspected focal areas of disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors, focal inflammatory or demyelinat... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) CZ (Completed) HU (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-003481-18 | Sponsor Protocol Number: CART.III. | Start Date*: 2008-11-17 |
Sponsor Name:TBF | ||
Full Title: PHASE III PROTOCOL COMPARING A MICROFRACTURE TREATMENT TO A CARTIPATCH® CHONDROCYTE GRAFT TREATMENT IN FEMORAL CONDYLE LESIONS | ||
Medical condition: Femoral condyles single lesion from trauma or osteochondritis dissequans with invalidant signs | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002992-34 | Sponsor Protocol Number: CRAD001ADE07 | Start Date*: 2006-07-20 |
Sponsor Name:Deutsches Herzzentrum Berlin | ||
Full Title: Monocenter, double blinded, prospective, randomized, placebo controlled study investigating prevention of Major Adverse Cardiac Events (MACE) after 6 months by systemic treatment with Everolimus af... | ||
Medical condition: coronary artery disease coronary intervention with bare metal stents | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2004-005218-35 | Sponsor Protocol Number: NSGO-CC-0301 | Start Date*: 2006-05-18 |
Sponsor Name:Nordic Society of Gynecological Oncology (NSGO) | ||
Full Title: A phase II study of management of the patients with locally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinoma | ||
Medical condition: Locally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006738-33 | Sponsor Protocol Number: CL-1205 | Start Date*: 2008-03-14 | |||||||||||
Sponsor Name:NatImmune A/S | |||||||||||||
Full Title: bLAC - A phase II double-blind, placebo controlled, clinical proof of concept trial of the efficacy of 8 weeks treatment of cutaneous warts with bLAC in immune suppressed, kidney transplanted patients | |||||||||||||
Medical condition: Cutaneous wart lesions on hands and/or feet at immune suppressed, kidney transplanted patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003495-31 | Sponsor Protocol Number: CCLL442X2201 | Start Date*: 2017-12-14 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, Investigator-and patient-blind, placebo-controlled, parallel group first in human and proof of concept study to evaluate the safety, tolerability, and efficacy of CLL442 in patients w... | |||||||||||||
Medical condition: Cutaneous Squamous Cell Carcinoma in situ (SCCis) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001835-36 | Sponsor Protocol Number: 68923 | Start Date*: 2008-07-09 | |||||||||||
Sponsor Name:Gedeon Richter Plc. | |||||||||||||
Full Title: Single center, exploratoric, open-label study to investigate the add-on effect of vinpocetin to the haemorheological effect of 100 mg acetyl-salicylicum in patients with chronic cerebrovascular dis... | |||||||||||||
Medical condition: Aspirin resistance in patients with chronic cerebrovascular disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000926-24 | Sponsor Protocol Number: HTX101-03L | Start Date*: 2020-08-17 | ||||||||||||||||
Sponsor Name:Heidelberg ImmunoTherapeutics | ||||||||||||||||||
Full Title: A Randomised, Double-Blind Phase II Trial of Topical HDIT101 versus Placebo in Patients with Chronic Recurrent HSV-1 Infection and Orolabial Lesion | ||||||||||||||||||
Medical condition: Chronic Herpes Simplex Virus-1 Infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002977-33 | Sponsor Protocol Number: Luc01AKSI | Start Date*: 2006-06-22 |
Sponsor Name:University Eye Hospital | ||
Full Title: Safety and efficacy of intravitreal injections of ranibizumab/Lucentis in combination with verteporfin photodynamic therapy (PDT) in patients with choroidal neovascularisation (CNV) secondary to ag... | ||
Medical condition: Age related macular degeneration (AMD) is the leading cause of blindness in individuals older than 50 years in the developed world. Eighty to ninety percent of rapid and severe vision loss due to A... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000200-32 | Sponsor Protocol Number: Version 3.0 19 December 2006 | Start Date*: 2007-05-09 |
Sponsor Name:KANEKA coorporation | ||
Full Title: First in Man Feasibility Study with the MAHOROBA Stent | ||
Medical condition: The study will be performed in patients with symptomatic coronary artery disease (chronic stable angina, silent ischemia, and acute coronary syndrome, excluding ST-elevation myocardial infarction) ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-001711-38 | Sponsor Protocol Number: PC CO 201/08 | Start Date*: 2008-12-16 |
Sponsor Name:Photocure ASA | ||
Full Title: An open dose-finding study of oral applied hexaminolevulinate (HAL) imaging in patients with suspicion or high risk of dysplasia or neoplasia in the colon | ||
Medical condition: Patients with suspicion or high risk of neoplasia in the colon | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-003584-11 | Sponsor Protocol Number: MACT-IBK-2015 | Start Date*: 2015-12-11 | ||||||||||||||||
Sponsor Name:Medical University Innsbruck | ||||||||||||||||||
Full Title: Matrix-associated autologous chrondrocyte transplantation for grade four cartilage lesions of the knee joint - clinical and radiological outcome in correlation to the initial cell count of the cho... | ||||||||||||||||||
Medical condition: Cartilage lesion | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000197-30 | Sponsor Protocol Number: UoL001289 | Start Date*: 2018-07-13 |
Sponsor Name:The University of Liverpool | ||
Full Title: Sodium Valproate for Epigenetic Reprogramming in the Management of High Risk Oral Epithelial Dysplasia | ||
Medical condition: High Risk Oral Epithelial Dysplasia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003886-33 | Sponsor Protocol Number: MH-148 | Start Date*: 2014-02-28 | |||||||||||
Sponsor Name:Bracco Imaging S.p.A. | |||||||||||||
Full Title: PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, TWO-ARM CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF MULTIHANCE® WITH 0.1 mmol/kg OF DOTAREM® AND 0.05 mmol/kg OF MULTIHANCE® WITH 0.1 mmol/kg OF DOTA... | |||||||||||||
Medical condition: Patients have confirmed or are highly suspected to have brain tumor(s) (primary or secondary), as determined by: • clinical/neurological symptomatology; • diagnostic testing, such as CT or previ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003666-41 | Sponsor Protocol Number: IJBMNLUMEN | Start Date*: 2013-05-27 | |||||||||||
Sponsor Name:Jules Bordet Institute | |||||||||||||
Full Title: The LuMEn study 177Lu-octreotate treatment outcome prediction using Multimodality imaging in refractory neuroEndocrine tumours | |||||||||||||
Medical condition: Patients with proved progressive (or refractory to standard systemic therapy available in Belgium at the time of inclusion) neuroendocrine tumors, not amenable to surgical resection with curative i... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005788-24 | Sponsor Protocol Number: BA2005/21/02 | Start Date*: 2007-02-15 |
Sponsor Name:Bioalliance Pharma | ||
Full Title: A Randomised, Double-Blind, Single dose, One-Day Early Administration, Multicentre Study comparing the Efficacy and Safety of Acyclovir Lauriad 50 mg muco-adhesive buccal tablet to matching Placebo... | ||
Medical condition: Herpes labialis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) DE (Completed) FR (Completed) GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.